Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15934593 | 0.92 | PREP (0.61) | PREPCHRM1CHRM2CHRM3CTSL | |
| SCHEMBL2097353 | 0.92 | PREP (0.61) | PREPCHRM1CHRM2CHRM3CTSL | |
| SCHEMBL6621402 | 0.92 | PREP (0.61) | PREPCHRM1CHRM2CHRM3CTSL | |
| SCHEMBL12294933 | 0.92 | PREP (0.61) | PREPCHRM1CHRM2CHRM3CTSL | |
| SCHEMBL6620964 | 0.92 | PREP (0.61) | PREPCHRM1CHRM2CHRM3CTSL | |
| SCHEMBL15934580 | 0.92 | PREP (0.61) | PREPCHRM1CHRM2CHRM3CTSL | |
| SCHEMBL17862217 | 0.92 | PREP (0.61) | PREPCHRM1CHRM2CHRM3CTSL | |
| SCHEMBL29545793 | 0.84 | PREP (0.59) | PREPCHRM1CHRM2CHRM3CTSL | |
| SCHEMBL4356385 | 0.84 | PREP (0.59) | PREPCHRM1CHRM2CHRM3CTSL | |
| SCHEMBL16071354 | 0.84 | PREP (0.59) | PREPCHRM1CHRM2CHRM3CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548901-B2 | Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210053988-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| US-10689399-B2 | Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190092787-A1 | SUBSTITUTED 2,3,4,5,7,9,13,13A-OCTAHYDRO-1,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[1,3]DIAZEPINES AND METHODS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2019-03-28 | — | — | US | disclosed |
| US-10035809-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170260204-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170260204-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9732092-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732092-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9663528-B2 | Substituted 1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663528-B2 | Substituted 1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170057976-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20160176885-A1 | SUBSTITUTED 1,2,3,4,6,8,12,12a-OCTAHYDRO-1,4-METHANODIPYRIDO[1,2-a:1',2'-d]PYRAZINES AND METHODS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176885-A1 | SUBSTITUTED 1,2,3,4,6,8,12,12a-OCTAHYDRO-1,4-METHANODIPYRIDO[1,2-a:1',2'-d]PYRAZINES AND METHODS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
| EP-2822954-B1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-9216996-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216996-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140221356-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140221356-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176885-A1 | SUBSTITUTED 1,2,3,4,6,8,12,12a-OCTAHYDRO-1,4-METHANODIPYRIDO[1,2-a:1',2'-d]PYRAZINES AND METHODS FOR TREATING VIRAL INFECTIONS | PYM1, ZC3HAV1, ZYX | PREP 1933/4885CHRM1 52/4885CHRM2 238/4885 |
| US-20190092787-A1 | SUBSTITUTED 2,3,4,5,7,9,13,13A-OCTAHYDRO-1,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[1,3]DIAZEPINES AND METHODS FOR TREATING VIRAL INFECTIONS | ZC3HAV1, PYM1, CCR5 | PREP 1778/4885CHRM1 18/4885CHRM2 111/4885 |
| US-10689399-B2 | Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections | PYM1, ZYX, XDH | PREP 2122/4885CHRM1 92/4885CHRM2 338/4885 |
| US-10035809-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections | PYM1, ZC3HAV1, CD4 | PREP 1918/4885CHRM1 22/4885CHRM2 100/4885 |
| US-20210053988-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZC3HAV1, PYM1, ZC3HAV1L | PREP 131/4885CHRM1 29/4885CHRM2 102/4885 |
| US-20140221356-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZC3HAV1, PYM1, ZC3HAV1L | PREP 131/4885CHRM1 29/4885CHRM2 102/4885 |
| US-20170057976-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZC3HAV1, PYM1, ZC3HAV1L | PREP 131/4885CHRM1 29/4885CHRM2 102/4885 |
| US-20170260204-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZC3HAV1, PYM1, ZC3HAV1L | PREP 131/4885CHRM1 29/4885CHRM2 102/4885 |
| US-11548901-B2 | Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections | PYM1, XDH, CYP2S1 | PREP 1749/4885CHRM1 119/4885CHRM2 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.